Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.
Positive
- None.
Negative
- None.
News Market Reaction – KYTX
In the Mar 3 session, KYTX declined 5.76%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Board refresh | Positive | +0.5% | Two experienced biotech leaders appointed to strengthen board oversight. |
| Feb 03 | CTO appointment | Neutral | +0.0% | New CTO with long cell and gene therapy manufacturing background. |
| Jan 12 | Corporate update | Positive | -1.1% | BLA timing, Phase 3 enrollment, IND acceptance and cash runway details. |
| Jan 05 | Conference presentation | Neutral | -7.3% | Planned presentation at major healthcare conference with webcast access. |
| Dec 17 | Equity offering | Negative | -32.5% | Pricing of $100M public offering of common stock at $7.50 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Capital-raising news drew the sharpest negative reaction, while governance and leadership updates saw mild or positive moves. Conference participation alone previously coincided with a notable selloff.
Over the last few months, Kyverna has focused on strengthening its balance sheet and leadership bench while advancing its CAR T pipeline. A $100M equity offering in Dec 2025 triggered a steep -32.52% reaction. Subsequent news emphasized strategic priorities, new CTO and board appointments, with mostly modest price moves (from -1.08% to +0.51%). A prior conference appearance on Jan 5 coincided with a -7.3% move, framing today’s conference-focused announcement against a mixed historical backdrop.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences:
Leerink Partners 2026 Global Healthcare Conference
Format: Fireside chat and investor meetings
Date: Monday, March 9th, 2026
Time: 11:20 a.m. ET
2026 Jefferies Biotech on the Beach Summit
Format: Investor meetings
Date: Tuesday, March 10th, 2026
A live webcast of the Leerink fireside chat may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. The Company’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its initial indications in stiff person syndrome and myasthenia gravis. The Company is also advancing additional clinical and investigator-sponsored studies, including in multiple sclerosis and rheumatoid arthritis, to inform future priority indications and develop next-generation CAR T platforms to improve access and patient experience. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
